Ground News

News from Optimum Strategic Communications

See all of Optimum Strategic Communications news coverage in one place. Discover how Optimum Strategic Communications’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 53 stories from Optimum Strategic Communications over the past 3 months.

Optimum Strategic Communications’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Optimum Strategic Communications’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Optimum Strategic Communications

Where is Optimum Strategic Communications located?Optimum Strategic Communications's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Optimum Strategic Communications News

Medical · Denmark

New Center in Copenhagen to Pioneer the Future of Protein Design

100% Center coverage: 1 sources

Proteins are the workhorses of biology. They perform virtually every important function in living organisms. They store, copy and protect our DNA, digest food to give us energy, and harness this energy to make our cells and muscles work.See the Story

England · England

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

100% Center coverage: 1 sources

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief Development Officer…See the Story

Breye Therapeutics Reports Completion of Phase 1b for Oral NPDR Therapy

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.See the Story

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence – Optimum Strategic CommunicationsLink to: Hot topic: Midsummer is here – winter is comingScroll to top

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from all over the globe, including Denmark, Sweden, The Netherlands, Belgium, Germany, Australia, and the USA. Read more…Artificial Intelligence · Denmark Read Article

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize – Optimum Strategic CommunicationsLink to: New Danish research centre to make designed proteins with vast potentialScroll to top

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]Innovation · Southampton Read Article

Weekly roundup: From BIO 2025 to building boards – Optimum Strategic CommunicationsLink to: Hot topic: Should we keep renaming diseases?Scroll to top

Rewind Therapeutics strengthens scientific advisory board with leading international neurology experts as it advances its first-in-class remyelination therapy Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has appointed four internationally recognised innovators in neurology – Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan – to its Scientific Advisory Boa…Read Article

Hot topic: Should we keep renaming diseases? – Optimum Strategic CommunicationsLink to: Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination TherapyScroll to top

Thursday June 12 was Global Fatty Liver Day. But until 2018 it was known as International NASH Day – NASH being short for ‘non-alcoholic steatohepatitis’. The name of the awareness day was changed to increase awareness of all types of fatty liver disease, as NASH is just one type – a more serious type – […]Professors · Leuven Read Article

Weekly roundup: Innovation and deals for Optimum’s clients – Optimum Strategic CommunicationsLink to: Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startupsScroll to top

SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]Nvidia Read Article

Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills - NVIDIA (NASDAQ:NVDA), Novo Nordisk (NYSE:NVO), IQVIA Hldgs (NYSE:IQV)

100% Center coverage: 2 sources

Founder and CEO of Nvidia Corp (NASDAQ:NVDA), Jensen Huang, announced on Wednesday that the company has inked two new large partnerships to advance its work in healthcare. The first is with European-based weight loss drug maker Novo Nordisk A/S (NYSE:NVO) to accelerate drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Also Read: Hyperfine, Nvidi…Nvidia · Denmark See the Story

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

100% Center coverage: 5 sources

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt diseaseFunding will also advance a broader pipeline…Startups See the Story

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria – Optimum Strategic CommunicationsLink to: AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSi

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]Neuried · Neuried Read Article

News from Optimum Strategic Communications

News from Optimum Strategic Communications

Information about Optimum Strategic Communications

Media Bias Ratings

Factuality

Ownership

Top Optimum Strategic Communications News

New Center in Copenhagen to Pioneer the Future of Protein Design

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

Breye Therapeutics Reports Completion of Phase 1b for Oral NPDR Therapy

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence – Optimum Strategic CommunicationsLink to: Hot topic: Midsummer is here – winter is comingScroll to top

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize – Optimum Strategic CommunicationsLink to: New Danish research centre to make designed proteins with vast potentialScroll to top

Weekly roundup: From BIO 2025 to building boards – Optimum Strategic CommunicationsLink to: Hot topic: Should we keep renaming diseases?Scroll to top

Hot topic: Should we keep renaming diseases? – Optimum Strategic CommunicationsLink to: Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination TherapyScroll to top

Weekly roundup: Innovation and deals for Optimum’s clients – Optimum Strategic CommunicationsLink to: Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startupsScroll to top

Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills - NVIDIA (NASDAQ:NVDA), Novo Nordisk (NYSE:NVO), IQVIA Hldgs (NYSE:IQV)

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria – Optimum Strategic CommunicationsLink to: AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSi

Similar News Topics

Topics Most Covered by Optimum Strategic Communications

Sources Covering Similar Topics

Breaking News Topics Related to Optimum Strategic Communications